Piramal Pharma Limited, a leading global pharmaceutical company, has announced the expansion of its biologics manufacturing infrastructure to meet the growing industry demand. The company has invested in new facilities and upgraded existing ones to enhance its capabilities in biologics manufacturing, process development, and analytical services.
The expansion is a strategic move to capitalize on the increasing demand for biologics, which are expected to drive the growth of the pharmaceutical industry in the coming years. Biologics are complex molecules that require specialized manufacturing facilities and expertise, and Piramal Pharma Limited is well-positioned to cater to this demand with its state-of-the-art infrastructure and team of experienced professionals.
The company’s biologics manufacturing facility is designed to meet the highest standards of quality and compliance, with features such as isolator technology, single-use bioreactors, and advanced process control systems. The facility has the capability to manufacture a range of biologics, including monoclonal antibodies, proteins, and vaccines, and can support clients from early-stage development to commercial-scale production.
Piramal Pharma Limited’s expansion plans include the addition of new laboratories, offices, and manufacturing suites, as well as the upgrade of existing equipment and systems. The company has also invested in the latest technologies, such as advanced chromatography and filtration systems, to enhance its biologics manufacturing capabilities.
The company’s biologics business has experienced significant growth in recent years, driven by the increasing demand for biologics and the company’s expertise in this area. Piramal Pharma Limited has a strong track record of delivering high-quality biologics products and services to its clients, and the expansion of its manufacturing infrastructure is expected to further strengthen its position in the market.
The expansion is also expected to create new job opportunities and drive economic growth in the region. Piramal Pharma Limited has a strong commitment to social responsibility and sustainability, and the company is working to minimize the environmental impact of its operations and promote social and economic development in the communities it serves.
Overall, Piramal Pharma Limited’s expansion of its biologics manufacturing infrastructure is a significant development that is expected to drive growth and innovation in the pharmaceutical industry. With its state-of-the-art facilities, experienced team, and commitment to quality and compliance, the company is well-positioned to meet the growing demand for biologics and deliver high-quality products and services to its clients.